Artivion’s (AORT) Buy Rating Reaffirmed at Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 10.55% from the company’s previous close.

A number of other equities analysts have also commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer lifted their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.80.

Artivion Stock Up 0.4 %

Shares of Artivion stock traded up $0.12 on Tuesday, hitting $30.76. 46,311 shares of the company traded hands, compared to its average volume of 351,062. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion has a 12-month low of $16.48 and a 12-month high of $32.33. The company has a 50-day moving average price of $29.15 and a 200 day moving average price of $27.33. The company has a market cap of $1.29 billion, a PE ratio of -1,540.75 and a beta of 1.74.

Insider Activity at Artivion

In other Artivion news, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the sale, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares in the company, valued at $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,017 shares of company stock worth $600,007. 8.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AORT. Quarry LP boosted its holdings in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the period. R Squared Ltd bought a new stake in shares of Artivion in the fourth quarter valued at approximately $39,000. GAMMA Investing LLC grew its position in Artivion by 21.8% during the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock worth $79,000 after buying an additional 497 shares in the last quarter. KBC Group NV increased its stake in Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company’s stock worth $80,000 after acquiring an additional 1,254 shares during the period. Finally, RiverPark Advisors LLC raised its holdings in Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after acquiring an additional 3,246 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.